Acrolein consumption induces systemic dyslipidemia and lipoprotein modification

Area of Science:

• Environmental Health
• Toxicology
• Cardiovascular Science

Background:

• Acrolein is a ubiquitous environmental pollutant found in smoke and industrial effluents.
• Oral intake is a primary route of exposure to acrolein and related aldehydes.
• Dyslipidemia is a significant risk factor for cardiovascular disease.

Purpose of the Study:

• To investigate the effects of short-term oral acrolein exposure on lipoprotein levels and metabolism in mice.
• To assess the impact of acrolein on hepatic gene expression related to lipid metabolism.

Main Methods:

• Adult mice were orally administered varying doses of acrolein.
• Plasma lipoprotein profiles, including cholesterol and triglyceride levels, were analyzed.
• Hepatic gene expression and enzyme activities (hepatic lipase) were examined using qRT-PCR and activity assays.
• Lipoprotein particle size and mobility were assessed via NMR and agarose gel electrophoresis.

Main Results:

• Acrolein exposure increased plasma cholesterol and triglycerides without affecting body weight or liver enzymes.
• Lipoprotein analysis revealed elevated VLDL cholesterol and triglycerides, with shifts in VLDL and LDL particle sizes.
• Decreased hepatic lipase activity and gene expression were observed in acrolein-fed mice.
• Similar dyslipidemic effects were noted in apoE-null mice, indicating a potential exacerbation of existing conditions.

Conclusions:

• Oral exposure to acrolein induces systemic dyslipidemia in mice.
• Acrolein's effects on lipoprotein metabolism, particularly VLDL, may contribute to cardiovascular disease risk.
• Further research is warranted to understand the clinical implications of acrolein exposure on human cardiovascular health.